Press release Communiqué de presse

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter

Press release Communiqué de presse


September 25, 2002 25 September, 2002

FDA Approves Pheromone Sciences' PSC Fertility Monitor


Toronto, Ontario (September 25, 2002) - Pheromone Sciences Corp (TSX Venture Exchange: PHS), today announced that it has received FDA approval for its PSC Fertility Monitor(tm). The approval permits PHS to commence marketing and distribution activities throughout the United States under the indicated use of Fertility and Ovulation Prediction, thus enhancing effective decision making in family planning. No other commercially available ovulation-monitoring device provides as much advanced notice of ovulation.

The PSC Fertility Monitor is a watch like fertility cycle monitoring device for the consumer and professional medical market. The PSC Fertility Monitor looks to set a new benchmark in providing a reliable "predictive" approach to natural, cycle-based family planning through the measurement of perspiration ion changes on the surface of the skin. These changes in female perspiration allow for the prediction of ovulation up to 4 days prior to the day of ovulation without the need for inconvenient urine or blood testing.

Following the release of U.S. clinical trial results earlier this year, Dr. Arthur Haney, Professor of Obstetrics and Gynecology of Duke University commented that, "Couples trying to conceive and using the PSC Fertility Monitor will be able to predict their ovulation date 4 days in advance for the first time and have the advantage of identifying the 6 days of maximum fertility: the 4 days before, the day of and the day after ovulation. This allows the couple to reduce the stress involved and with intercourse on multiple days, increase their cumulative likelihood of pregnancy."

Currently, the North American market for fertility related products is valued at about US$450 million and forecast to grow to in excess of US$560 million by 2007."We are confident that the consumer uptake of our product will be very encouraging", said Christopher Neuman, President and CEO of Pheromone Sciences Corp. "With this important milestone achieved, our attention will be focused on generating revenue for the Company".

A specific web site www.fertiliteOV.com has been created for the monitor where couples can access specific information about the product offering.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Pheromone Sciences Corp is a member of MEDEC, which is the national industry association representing over 120 medical device and diagnostic companies. Member companies are dedicated to serving the health care community through the provision of high quality medical products and services that benefit Canadians.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Ventures Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.